Trial Profile
Efficacy and Safety of the Combination of Reduced Duration Prophylaxis Followed by Immuno-guided Prophylaxis to Prevent Cytomegalovirus Disease in Lung Transplant Recipients (CYTOCOR STUDY): An Open-label, Randomised, Non-inferiority Clinical Trial.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Sep 2023
Price :
$35
*
At a glance
- Drugs Ganciclovir (Primary) ; Valganciclovir (Primary)
- Indications Cytomegalovirus infections
- Focus Therapeutic Use
- Acronyms CYTOCOR
- 14 Sep 2023 Status changed from active, no longer recruiting to completed.
- 02 Mar 2023 Status changed from recruiting to active, no longer recruiting.
- 11 Nov 2019 Status changed from not yet recruiting to recruiting.